Background and Aims: The ECCO-EpiCom study investigates the differences in the incidence and therapeutic management of inflammatory bowel diseases [IBD] between Eastern and Western Europe. The aim of this study was to analyse the differences in the disease phenotype, medical therapy, surgery, and hospitalization rates in the ECCO-EpiCom 2011 inception cohort during the first year after diagnosis. Conclusions: During the first year after diagnosis, surgery and hospitalization rates were significantly higher in CD patients in Eastern Europe compared with Western Europe/Australia, whereas significantly more CD patients were treated with biologicals in the Western Europe/ Australian centres.
Introduction
Inflammatory bowel diseases [IBD] , including Crohn's disease [CD] and ulcerative colitis [UC] , are chronic, relapsing conditions requiring frequent contact by the patients with healthcare providers.
Hospitalization and surgery rates are important outcome measures and indicators of disease severity in IBD. The management of both CD and UC has changed significantly in the past two decades, with early acceleration of therapeutic steps including introduction of immunosuppressive [IS] and anti-TNF therapy. A recent metaanalysis by Bernstein et al. for the International Organization for the Study of Inflammatory Bowel Diseases [IOIBD] , analysing the surgery and hospitalization rates in population-based studies from the pre-biological era, reported declining surgery rates and unchanged/ declining hospitalization rates, but the impact of the biological therapy on the disease course, including surgical and hospitalization rates, is awaited. 1 The European Crohn's and Colitis Organisation-Epidemiological Committee [ECCO-EpiCom] study initiated in 2010 investigates the differences in the incidence, disease characteristics, and therapeutic management of IBD between Eastern and Western Europe. The higher incidence rates for IBD found in the Western European centres in the 2010 inception cohort were repeated in the 2011 inception cohort. 2, 3, 4 The 1-year follow-up of the 2010 cohort revealed higher use of biological agents in Western Europe compared with Eastern Europe, but surgical and hospitalization rates did not differ between these two geographical regions and they were similar to the results reported in recent population-based studies. 5 Interestingly, in the 2011 inception cohort, the number of CD patients with complicated disease behaviour [stricturing and/or penetrating ± perianal involvement] was more frequent in the Eastern European centres compared with the Western European centres. The disease characteristics were not different between the Western European and Australian CD patients. 3 In the present study our aim was to compare the disease phenotype, therapeutic strategy, and surgery and hospitalization rates during the first year after diagnosis between the participating Eastern European and Western Europe/Australian centres in the 2011 ECCO-EpiCom inception cohort.
Materials and Methods
A total of 14 centres-4 centres from Eastern Europe, 9 centres from Western Europe and 1 centre from Australia-participated in the 1-year follow-up of the ECCO-EpiCom 2011 inception cohort.
The methodology of the case ascertainment and data collection of the present cohort was the same as the ECCO-EpiCom 2010 inception cohort. 6 Newly diagnosed IBD patients between 1 January and 31 December 2011 were included in the 2011 ECCO-EpiCom inception cohort. For participation in the incident cohort, a well-defined up-take area with up-to-date demographics on the background population [age and gender distribution] was required. General practitioners and specialists in the local area were informed about the inception cohort by local investigator meetings or letters, and centres contacted them twice a year regarding patient file information of incident IBD patients. Patients' data regarding disease characteristics, medical therapy, and events such as hospitalizations, surgery, pregnancy, cancer, and death were registered and data were entered by physicians and/or IBD specialist trained nurses into the web-based EpiCom database [www.epicom-ecco.eu] every third month during the first year after diagnosis. The validity of the data was enhanced by built-in control and validation tests, manual data standardisation and random audits of case ascertainment and data quality. 3, 7 For identifying CD, UC, and IBD unclassified [IBDU], the Copenhagen Diagnostic Criteria 8, 9 were applied by all participating centres. Location and disease behaviour of CD, as well as the extent of UC, were defined according to the Montreal classification. 10 Definition of treatment steps: treatment was grouped into five levels stratified by therapeutic potency: 5-aminosalicylates [5- A p-value of <0.05 was considered statistically significant.
Ethical statement
The study was approved by the local ethics committees according to local regulations. During the first year of follow-up, 12 [2%] patients from Western Europe/Australia and no patients from Eastern Europe changed diagnosis. Out of the 10 IBDU patients, 6 patients changed diagnosis to CD and 4 patients to UC, and 2 UC patients changed diagnosis to CD.
Results

Out
Treatment steps during the first year of followup
The probability of highest level of treatment steps reached within 1 year after diagnosis in CD and UC in Eastern and Western Europe/ Australia is illustrated in Figures 1 and 2 In IBDU, 13 [19%] patients were hospitalized in Western Europe/ Australia during the first year after diagnosis, with a second hospitalization rate of 38%.
Surgery
In CD, 17 [24%] patients from Eastern Europe and 13 [7%] patients from Western Europe/Australia underwent surgery within the first year after diagnosis [p < 0.001, pLogRank = 0.001; Figure 4 . In Eastern Europe, the need for surgery was associated to ileal-only location and stricturing behaviour [pLogRank Loc = 0.008, pLogRank Beh < 0.001]. In both regions, disease behaviour was the major driver for surgery [pLogRank <0.001; Figure S1d , available as Supplementary data at JCC online.]. One CD patient from Eastern Europe and one from Western Europe/Australia required reoperation within the first year after diagnosis. In Western Europe/Australia, five CD patients received biological therapy before surgery. Out of these patients, three patients had stricturing and two patients had penetrating disease behaviour, and the disease location was ileal in three and colonic in two patients. In Eastern Europe, biological therapy was not introduced before surgical procedure in CD patients. In a multivariate logistic regression model, disease behaviour and geographical region were independent predictors for surgery [ 
Death
Three [0.4%] patients died during the first year of follow-up; one CD patient with ileal localisation and penetrating disease behaviour from Eastern Europe died due to sepsis after IBD-related major surgery. One CD and one UC patient from Western Europe died from non-IBD-related causes.
Cancer
One gastrointestinal in situ carcinoma and three cases of extra-intestinal cancer occurred in four [0.6%] Western European/Australian patients [two CD, one UC, and one IBDU] during the follow-up period with, respectively, dysplastic polyp of the sigmoid colon, cancer of the respiratory and intrathoracic organs, skin cancer, and breast cancer. The UC patient with a dysplastic polyp of the sigmoid colon underwent a surgical resection.
Discussion
In this pan-European population-based inception cohort of patients with IBD, hospitalization and surgery rates in CD differed significantly between Eastern and Western Europe/Australia and there was a higher use of biologicals in Western Europe/Australia.
Significantly more CD patients from Eastern Europe underwent a surgical procedure within the first year of follow-up compared with Western Europe/Australia [24% vs 7%]. The corresponding rate during the first 3 months after diagnosis was 14% in the Eastern European CD patients, indicating early and inevitable surgeries with more than half of these cases having surgery by 1 year. 3 Interestingly, similar early surgery rates were reported by a retrospective cohort study by Cosnes et al. including CD patients diagnosed between 1978 and 2002; 15% of the patients underwent a surgical procedure within the first 3 months following diagnosis, but after the first 3 months, the surgery rate was 3.3-5.7% with no significant change over the 26 years. 11 In contrast, surgery rates found in Western Europe/Australia are similar or somewhat lower compared with the results of recent population-based studies. 5, 12, 13, 14 As the disease behaviour was the major driver for surgical procedures in both regions, the higher surgery rates observed in Eastern European CD patients can be explained by the differences in the disease phenotype between the Eastern European and Western European/Australian CD patients, with a significantly higher percentage of patients with complicated disease behaviour in Eastern Europe.
Ileal-only localisation and stricturing disease behaviour were associated with the need for surgery in CD patients from the participating Eastern European centres. This may partly represent a treatment decision for limited surgery driven by the clinician rather than the disease phenotype, as highlighted also in the logistic regression model. Of note, significantly more patients with B2 behaviour received biological therapy in Western Europe/Australia compared with Eastern Europe (27.6% vs 5.3% [1 patient], p = 0.05] during the first year after the diagnosis. This result corresponds to the findings of the Inflammatory Bowel South-Eastern Norway [IBSEN] population-based cohort study conducted between 1990 and 1994, where terminal ileal localisation, stricturing, and penetrating disease behaviour were independent risk factors for surgery. 15 In the population-based cohort study from Veszprem Province, Hungary, ileal 17 In CD, a significantly higher hospitalization rate was found in the Eastern European centres compared with the Western European centres [34% vs 21%, p = 0.02]. In the meta-analysis from Bernstein et al., hospitalization rates in the population-based studies from the pre-biological era were varying between 25-83% ,with the highest rates observed in the first year following the CD diagnosis. , and of the 2010 ECCO-EpiCom cohort. 5 Of note, hospitalization rates and access to biological therapy should be interpreted with caution due to significant differences in local insurance policies and ethnic background across countries.
The higher use of biological therapy in the Western European/ Australian centres is in line with the results from the 2010 ECCOEpiCom cohort. 5 The impact of this more aggressive medical therapeutic approach on long-term disease course and surgery rates needs to be further evaluated.
In conclusion, in the this prospective, population-based inception cohort of IBD patients, higher surgery and hospitalization rates were found in CD patients in the Eastern European centres, associated with the higher proportion of stricturing and penetrating disease behaviour in this patient group. More than half of the surgical procedures were performed within the first 3 months after diagnosis. In Eastern Europe, ileal-only location and stricturing disease behaviour were predictors for surgery, which may partly represent a medical decision. Interestingly, there was still a high exposure of 5-ASAs in CD in both regions. In UC, disease extent, surgery and hospitalization rates, and use of biologicals did not differ between Eastern Europe and Western Europe/Australia and surgical rates were reassuringly low. [Australia], A Nicolaou 
